BioSpace News Archive

Children’s Hospital of Philadelphia announced that it has received a significant philanthropic gift from Mitchell L. Morgan, Dr. Hilarie L. Morgan and their family to name its state-of-the-art research facility currently under construction on the South Street bridge next to CHOP’s Roberts Center for Pediatric Research.

CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2024.

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder, announced that it closed upon the initial tranche of a private placement pursuant to the Securities Purchase Agreement with an institutional investor.

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced the forthcoming prospective validation of its groundbreaking diagnostic tool HER2DX® within the framework of the ongoing CompassHER2 pCR Trial.

The Maryland Stem Cell Research Commission is pleased to announce the next round of awards granting a total of more than $15.4 million.

Amygdala Neurosciences announced that the Company has closed a new round of equity financing led by ABMRF, the Alcohol Beverage Medicines Research Foundation to fund the Company’s IND-stage activities for ANS-858.

Biophytis SA announces the design of its phase 2 OBA clinical study in obesity with BIO101.

Element Biosciences, Inc., developer of pioneering technologies to empower science, announced record growth in installations of its AVITI™ System ahead of its participation in upcoming investor conferences.

Castle Biosciences, Inc. will share three abstracts supporting the ability of its TissueCypher® test to predict risk of progression to esophageal cancer in patients with Barrett’s esophagus (BE) at the Digestive Disease Week (DDW) 2024 Annual Meeting, being held May 18-21, 2024, in Washington, D.C.

Tavros Therapeutics, Inc., a precision oncology platform company, announced that the Company has achieved two milestone payments in its collaboration with Vividion Therapeutics, Inc., a wholly owned and independently operated subsidiary of Bayer AG.